NICOCCINO SIGNS AGREEMENT WITH AN AMERICAN MANUFACTURER
In beginning of 2016, Nicoccino Holding AB took a new strategic direction with focus to license the Company’s unique nicotine strip. One main criteria to succeed with this drug classification is to identify a new producer. The Company has now signed an agreement with an American manufacturer who fulfills all regulatory requirements.
”I am very happy that Nicoccino, after extensive efforts to secure a qualified partner, has finally signed an agreement with a producer that has deep knowledge and experience in develop and produce pharmaceuticals. We see that our partner has the flexibility and capacity that we pursued to fit Nicoccino’s future strategy.” says Anders Ulfhielm, CEO for Nicoccino Holding AB.
With the new agreement, Nicoccino Holding AB can now initiate the first phase with technical transfer and relevant tests to start production for the clinical trials.
Nicoccino has developed an innovative and patented nicotine product that after completion of a clinical study will be classified as a medicine for smoking cessation (Nicotine Replacement Therapy – NRT). Sales to consumers will be managed indirectly through a license model with international partners.
Nicoccino`s head quarter is located in Täby outside of Stockholm. The company’s share has been listed on Nasdaq First North since June 2014 and can be found under the abbreviation NICO.
Remium Nordic AB is Nicoccino Holding’s Certified Adviser.
This information is information that Nicoccino Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above at 08:00 CET on 18th Oct. 2016. This message has been communicated in Swedish and English. If differences between the versions exist, the Swedish version is pertained.
Anders Ulfhielm, CEO, Nicoccino Holding AB
+4670-594 7618 firstname.lastname@example.org
Nicoccino has developed a patented, innovative and discrete strip that through its unique delivery method instantly provides the user with nicotine without the detrimental side effects of smoking. The product is designed to offer smokers an attractive alternative when they want to quit smoking. After a pharmaceutical approval, the product will be sold as a smoking cessation drug (Nicotine Replacement Therapy – NRT).
Some cookies are required to give you access to the website, while others are used to upgrade your user experience and are voluntary to accept. Choose below if you agree to us processing cookies to enable and analyze the provision of functionalities by third parties (eg social media plugins) and improve your user experience by analyzing your use of the website.